Efficacy Study of Vaginal Mesh for Prolapse (VAMP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Medstar Research Institute.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Washington Hospital Center
Information provided by:
Medstar Research Institute
ClinicalTrials.gov Identifier:
NCT00475540
First received: May 17, 2007
Last updated: August 4, 2009
Last verified: August 2009

May 17, 2007
August 4, 2009
January 2007
January 2010   (final data collection date for primary outcome measure)
All POPQ points (Ba, Bp or C) at Stage I (defined as descent of the leading edge to >1 cm above hymen) or less at one year. [ Time Frame: 3 year ] [ Designated as safety issue: No ]
Apical Prolapse, point C at Stage I or less at one year. [ Time Frame: 3 year ]
Complete list of historical versions of study NCT00475540 on ClinicalTrials.gov Archive Site
To compare patient satisfaction and Quality of Life (QOL) variables between the two arms of the trial. We will also assess complications and subjective cure rates of overall incontinence and lower urinary tract function. [ Time Frame: 3 year ] [ Designated as safety issue: Yes ]
To compare patient satisfaction and Quality of Life (QOL) variables between the two arms of the trial. We will also assess complications and subjective cure rates of overall incontinence and lower urinary tract function. [ Time Frame: 3 year ]
Not Provided
Not Provided
 
Efficacy Study of Vaginal Mesh for Prolapse
A Randomized Clinical Trial of Vaginal Mesh for Prolapse

The primary aim of this double-blind, randomized clinical trial (RCT) is to test the hypothesis that the addition of a standardized technique of interpositional synthetic polypropylene mesh placement improves the one-year outcome of vaginal reconstructive surgery for pelvic organ prolapse compared to traditional vaginal reconstructive surgery without mesh.

Minimally invasive surgical procedures using mesh have rapidly developed in the field of pelvic floor reconstruction. Unfortunately, safety and efficacy data have lagged behind the technical advancements. No randomized controlled trials of different vaginal apical suspension procedures have been reported. The use of synthetic vaginal mesh has evolved due to the 20-30% recurrence rate for conventional pelvic reconstructive surgeries. This trial will examine synthetic monofilament polypropylene mesh use in vaginal reconstructive surgery for vaginal Stage II-IV prolapse.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
  • Pelvic Organ Prolapse
  • Uterine Prolapse
  • Vaginal Prolapse
  • Cystocele
  • Rectocele
Device: synthetic monofilament polypropylene mesh
Vaginal prolapse repair with mesh
Other Name: Prolift
  • Active Comparator: Prolift mesh
    vaginal prolapse repair with mesh
    Intervention: Device: synthetic monofilament polypropylene mesh
  • Active Comparator: Prolapse repair without mesh
    vaginal prolapse repair without mesh
    Intervention: Device: synthetic monofilament polypropylene mesh
Iglesia CB, Sokol AI, Sokol ER, Kudish BI, Gutman RE, Peterson JL, Shott S. Vaginal mesh for prolapse: a randomized controlled trial. Obstet Gynecol. 2010 Aug;116(2 Pt 1):293-303.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
90
January 2011
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Woman > 21 yrs
  • Stage II-IV vaginal prolapse
  • Desires vaginal reconstructive surgery
  • Able to complete study questionnaires and assessments
  • Uterus < 12 weeks size
  • Available for 12 months follow-up

Exclusion Criteria:

  • Medical contraindications, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use or a compromised immune system.
  • Current intermittent catheterization.
  • Pregnancy or desire for future fertility.
  • Presence of an adnexal mass.
  • Shortened vagina or other known Mullerian anomaly (e.g. uterine didelphys).
  • Other laparoscopic or abdominal/pelvic surgery in the past 3 months.
  • Known neurologic or medical condition affecting bladder function, e.g. Multiple Sclerosis, spinal cord injury.
  • Need for concomitant surgery requiring an abdominal incision.
  • < 12 months post-partum.
  • Non-english speaking
Female
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00475540
2006-232
Yes
Cheryl Iglesia, MD, Washington Hospital Center
Medstar Research Institute
Washington Hospital Center
Principal Investigator: Cheryl Iglesia, MD Washington Hospital Center
Medstar Research Institute
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP